Loncar Cancer Immunotherapy ETF (CNCR)
CNCR is a passive ETF by Exchange Traded Concepts tracking the investment results of the Loncar Cancer Immunotherapy Index. CNCR launched on Oct 13, 2015 and has a 0.79% expense ratio.
ETF Info
ISIN | US26922A8264 |
---|---|
CUSIP | 26922A826 |
Issuer | Exchange Traded Concepts |
Inception Date | Oct 13, 2015 |
Region | Developed Markets (Broad) |
Category | Health & Biotech Equities |
Index Tracked | Loncar Cancer Immunotherapy Index |
Asset Class | Equity |
Asset Class Size | Multi-Cap |
Asset Class Style | Blend |
Expense Ratio
The Loncar Cancer Immunotherapy ETF has a high expense ratio of 0.79%, indicating higher-than-average management fees.
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: CNCR vs. IBBQ, CNCR vs. SCHD, CNCR vs. SMH, CNCR vs. OLGAX, CNCR vs. XMHQ
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Loncar Cancer Immunotherapy ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Loncar Cancer Immunotherapy ETF had a return of 8.91% year-to-date (YTD) and 13.94% in the last 12 months.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | 8.91% | 5.90% |
1 month | -9.78% | -1.28% |
6 months | 41.74% | 15.51% |
1 year | 13.94% | 21.68% |
5 years (annualized) | -4.31% | 11.74% |
10 years (annualized) | N/A | 10.50% |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | 5.12% | 21.96% | -3.76% | |||||||||
2023 | -8.86% | -11.64% | 13.69% | 22.40% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
Loncar Cancer Immunotherapy ETF(CNCR)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Loncar Cancer Immunotherapy ETF granted a 0.00% dividend yield in the last twelve months. The annual payout for that period amounted to $0.00 per share.
Period | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|---|---|
Dividend | $0.00 | $0.00 | $0.00 | $1.85 | $0.29 | $0.00 | $0.00 | $0.35 | $0.00 | $0.11 |
Dividend yield | 0.00% | 0.00% | 0.00% | 7.79% | 0.91% | 0.00% | 0.00% | 1.47% | 0.00% | 0.37% |
Monthly Dividends
The table displays the monthly dividend distributions for Loncar Cancer Immunotherapy ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | $0.00 | $0.00 | $0.00 | |||||||||
2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.85 |
2020 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.29 |
2019 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2018 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2017 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.35 |
2016 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2015 | $0.11 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Loncar Cancer Immunotherapy ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Loncar Cancer Immunotherapy ETF was 72.14%, occurring on Oct 27, 2023. The portfolio has not yet recovered.
The current Loncar Cancer Immunotherapy ETF drawdown is 55.77%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-72.14% | Feb 9, 2021 | 684 | Oct 27, 2023 | — | — | — |
-49.98% | Mar 13, 2018 | 506 | Mar 16, 2020 | 180 | Nov 30, 2020 | 686 |
-39.92% | Nov 30, 2015 | 51 | Feb 11, 2016 | 518 | Mar 5, 2018 | 569 |
-9.59% | Oct 16, 2015 | 4 | Oct 21, 2015 | 8 | Nov 2, 2015 | 12 |
-6.97% | Jan 20, 2021 | 7 | Jan 28, 2021 | 7 | Feb 8, 2021 | 14 |
Volatility
Volatility Chart
The current Loncar Cancer Immunotherapy ETF volatility is 10.34%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.